American Biotech Breaks Through on COVID-19


By John Stanford

Biotech companies are racing to develop a coronavirus vaccine. Massachusetts-based Moderna, for instance, recently received FDA approval to begin Phase II clinical trials of its experimental COVID-19 vaccine. Pfizer, Novartis, and dozens of lesser-known innovators are close behind.

Unfortunately, some lawmakers could inadvertently make these companies' jobs much harder.

Several House lawmakers have recently pledged to preemptively strip patent protections from vaccine inventors. These lawmakers claim such measures will help patients by preventing "Big Pharma" from price-gouging.

Their concern for patients is admirable -- but their plan is misguided. The entire biomedical research ecosystem depends on intellectual property protections. Instead of helping patients, this effort would slow the development of treatments for the coronavirus and other deadly illnesses.

To see why patents are so essential to drug development, just look at Moderna's history.

In 2010, Boston Children's Hospital researcher Derrick Rossi filed to patent a method for generating stem cells with modified messenger RNA (mRNA). In principle, the foundational process could create any protein or antibody -- resulting in a vast array of powerful new therapies and vaccines.

The potential value of this novel idea, and the fact that Rossi had secured a patent -- thus blocking others from stealing his technique -- helped the brilliant researcher attract much-needed investment from Flagship Ventures (now Flagship Pioneering), a life-sciences venture firm which worked with Rossi and several partners to launch Moderna.

From there, a team of scientists and entrepreneurs experimented with Rossi's basic research hoping to produce a viable medical technology. Along the way, they patented their breakthroughs to safeguard their clinical research data against rival firms. As with most biotech ventures, this process was expensive and time-consuming.

Despite this risk, investors backed the firm. In 2013, Moderna received an upfront investment of $240 million from pharmaceutical giant AstraZeneca. To date, the company has raised $3.2 billion, but has yet to produce a marketed drug. That funding helped lay the groundwork for a robust biopharmaceutical pipeline of 21 drug candidates -- 13 of which are in clinical studies.

Now, the same proprietary mRNA is driving Moderna's speedy response to COVID-19. It enabled the development of a COVID-19 vaccine candidate just 42 days after genetic sequencing.

Moderna's story is one of thousands that exemplifies how academic research, private investment, and intellectual property laws all work together to drive innovation. This intricate ecosystem has made our country the world's leader in biopharmaceutical discovery, producing nearly two-thirds of new medicines.

That experimentation is not cheap. It takes over $2 billion, on average, to create a single successful drug -- largely because the majority of compounds don't survive clinical trials.

Absent strong market incentives and intellectual property protections, investors and companies wouldn't be able to recoup risky investments.

Investment funding would dry up -- and as a result, scientists would develop fewer new medicines.

That's why it's so troubling that some policymakers are pushing measures that would upend the life-sciences ecosystem. The House passed a sweeping drug package that would allow the government to cap the prices of many medicines. The Trump administration has considered a similar policy.

Other reforms would allow the government to dictate the prices of medicines tied in any small part to government-funded research.

Policies like these would make the already precarious process of drug development impossible. If the government reserves the right to dictate drug prices and take patents, the next Moderna would never get off the ground.

John Stanford is the executive director of Incubate, a coalition of life science venture capitalists based in Washington, D.C.

More Resources


03/29/2024
Behind Scenes Stories of Censorship


more info


03/29/2024
Where RFK Jr. Goes From Here


more info


03/29/2024
Will the RFK Factor Make a Difference in 2024?
Robert Kennedy Jr. leads the highest-polling independent presidential ticket in over 30 years

more info


03/29/2024
Democrats May Keep the Senate--With a Little GOP Help
The inexplicable determination of the party's voters to pick unstable provocateurs might be the only path Democrats have to hanging onto their narrow and very much endangered Senate majority.

more info


03/29/2024
You Count Votes Over and Over Until They Add Up Right
By John Kass March 27, 2024 Illinois Gov. J.B. Pritzker-the perpetually frightened rich kid born on third base thinking he hit a triple-has a big fat political problem. He's hosting the Democratic National Convention, his big fat coming out party in Chicago, in August. His fantasy? Becoming president of the United States of America. As he's planning his party, America ... Read More

more info


03/29/2024
The Long Road Back for the Port of Baltimore
For the moment, Maryland officials are focused on crisis management.

more info


03/29/2024
Enough Already
City leaders keep searching for the root cause of crime-they should look in the mirror.

more info


03/28/2024
The Democrats' Abundance Problem Revisited
Last week, I started revisiting my "Three Point Plan to Fix the Democrats and Their Coalition" from October of 2022. A brisk tour of the polling and political data suggested the Democrats are still in need of serious reform and that the three point plan is as relevant as ever. Here's the very short version of the plan:

more info


03/28/2024
Are Democrats Still Stuck With Biden?
Voters don't think much of the president but also remain wary of the obvious replacement.

more info


03/28/2024
What the Polls Say: RFK Jr. Hurting Biden, Helping Trump
In October, when Robert F. Kennedy Jr. abandoned his primary challenge to Joe Biden and instead launched an independent candidacy, the initial conventional wisdom was that he might hurt Donald Trump more than Biden.

more info


03/28/2024
The Twilight of the Republican 'McLeadership'
The Trump team is steadily purging the Republican leadership of holdovers from past decades. The departure of McCarthy, McDaniel, and McConnell is part of exorcising the legacy of a more important Mc whose influence is still felt in the U.S. Senate: John McCain.

more info


03/28/2024
The Funniest Media Story of the Year?
The following three things were obvious before MSNBC puked on itself in its public divorce with former RNC chief Ronna McDaniel, but aren't we glad the network didn't notice? More later, but briefly:

more info


03/28/2024
Abridging, Not Coercing, Is First Amendment's Yardstick
Under the First Amendment, the government may not abridge the freedom of speech, whether that abridging is done by coercing internet platforms or by getting them to cooperate in government efforts to censor the public.

more info


03/28/2024
Trade Cheaters Are Killing Aluminum Industry Jobs
Aluminum industry workers stand ready to do their part to move the nation forward. They just need the federal government to enforce trade laws.

more info


03/28/2024
It's Time for an Immigration Moratorium
An effective freeze on immigration could revitalize our national culture, politics, and economy before it's too late.

more info



Custom Search

More Politics Articles:

Related Articles

Americans Can't Afford Insurance — and Obamacare is to Blame


The number of uninsured Americans rose in 2018 for the first time since the Affordable Care Act passed in 2010, according to the Census Bureau.

ICER Discriminates Against People with Rare Diseases


FDA officials approved a record number of rare disease treatments last year. One groundbreaking medicine treats an inherited bone condition that causes intense pain and immobility. Another treats Fabry disease, a genetic condition that can lead to kidney failure or stroke.

Minor Legislation with Massive Implications


U.S. Senator Ron Johnson (R-WI) is promoting the "Prevent Government Shutdown Act of 2019." The goal of the act is to prevent disruptive government shutdowns.

When Humans Don't Procreate


The "hook" of the story intrigued me: "This hasn't happened in all of modern history..." An email from "The Crux" last month blared, "Global population growth to virtually stop by 2100."

Beware of Bills in Sheep's Clothing


There is a bipartisan tradition of naming bills such that no reasonable person would oppose them. For instance, changes to our tax system came with the passage of the Tax Cuts and Jobs Act. Who's against jobs? And how could anyone have voted against the Patient Protection and Affordable Care Act (i.e., "Obamacare")?

Offshore Bans Hurt Working Class Americans


Congressional Democrats just betrayed America's working class.

If You Like Your Health Plan, You Can't Keep It Under a Public Option


Nearly two in three Americans support the creation of a government-sponsored health plan to compete against plans offered by private insurers, according to the most recent survey data from the Kaiser Family Foundation.

Don't Legalize Discrimination Against People With Disabilities


Imagine if the federal government treated disabled Americans as second-class citizens. It's an appalling thought. But it could happen soon -- if some special interest groups get their way.

It's Time to Turn the Prescription Drug Debate on its Head


Politicians typically blame drug companies for soaring pharmacy prices. But insurers, pharmacies, and other middlemen are the real driving force behind rising drug spending.

U.S. Carbon Emissions Are Actually Dropping


Increased natural gas consumption helped bring down U.S. greenhouse gas emissions in 2019, according to a recent report from the U.S. Energy Information Administration.

"Buy American" Executive Order Could Slow Delivery of a Coronavirus Cure


President Trump is considering a "Buy American" executive order requiring government agencies to purchase medicines and medical supplies domestically.

Don't Disrupt the Supply Chain in the Midst of a Pandemic


The Trump administration fears America has lost its ability to mass-produce the medicines and medical supplies needed to fight the coronavirus and other, future pandemics. So it's considering an executive order to bring drug and medical-supply manufacturing back to the United States.

Intellectual Property Makes Sure Drug Makers Deliver


House Democrats Peter DeFazio, Rosa DeLauro, Lloyd Doggett, and Jan Schakowsky want to nullify intellectual property rights on any experimental treatments for COVID-19. They believe their proposals will prevent "price gouging and profiteering" without harming innovation.

Move These Projects Forward and Get America Back to Work


With more than 40 million Americans out of a job due to the coronavirus pandemic, states are scrambling to help the unemployed and laying plans to reopen the economy.

COVID-19 Cost-Effectiveness Research Deepens Racial Disparities


A newly released study by the Institute for Clinical and Economic Review (ICER), a Boston-based nonprofit, attempts to answer a weighty question: How much should it cost to treat the coronavirus?